The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development.
Dll 4
endometrial cancer
notch signaling pathway
prognostic role
toll-like receptors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Mar 2022
24 Mar 2022
Historique:
received:
09
02
2022
revised:
05
03
2022
accepted:
18
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
The Notch signaling pathway regulates the development of embryonic and tissue homeostasis of various types of cells. It also controls cell proliferation, variation, fate and cell death because it emits short-range messages to nearby cells. The pathway plays an important role in the pathophysiology of various malignancies, controlling cancer creation. It also limits cancer development by adjusting preserved angiogenesis and cellular programs. One of the Notch signaling ligands (in mammals) is Delta-like ligand 4 (Dll4), which plays a significant role in the overall malignancies' advancement. Particularly, sequencing Notch gene mutations, including those of Dll4, have been detected in many types of cancers portraying information on the growth of particular gynecological types of tumors. The current research article examines the background theory that implies the ability of Dll4 in the development of endometrial and other cancer types, and the probable therapeutic results of Dll4 inhibition.
Identifiants
pubmed: 35406423
pii: cancers14071649
doi: 10.3390/cancers14071649
pmc: PMC8996945
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E402-9
pubmed: 25605936
Arch Med Res. 2020 Feb;51(2):145-152
pubmed: 32111499
Clin Cancer Res. 2020 May 15;26(10):2393-2403
pubmed: 32034078
J BUON. 2021 Jul-Aug;26(4):1327-1332
pubmed: 34564988
Cancer Res. 2011 Sep 15;71(18):6030-9
pubmed: 21795478
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
Biochim Biophys Acta. 2013 Feb;1830(2):2481-95
pubmed: 23196196
Oncoscience. 2020 Jun 8;7(9-10):68-69
pubmed: 33195736
Cell Stem Cell. 2009 Aug 7;5(2):168-77
pubmed: 19664991
Eur J Immunol. 2017 Feb;47(2):385-393
pubmed: 27873300
Oncoimmunology. 2014 Jan 1;3(1):e27400
pubmed: 24701374
Cancer Cell. 2013 Feb 11;23(2):171-85
pubmed: 23375636
Int J Mol Sci. 2020 Dec 29;22(1):
pubmed: 33383646
Cancer Res. 2011 Sep 15;71(18):6061-72
pubmed: 21788346
Annu Rev Immunol. 2003;21:335-76
pubmed: 12524386
J Immunol Res. 2021 May 29;2021:9914854
pubmed: 34195298
Cell Cycle. 2010 Jan 1;9(1):80-5
pubmed: 20016278
Clin Cancer Res. 2015 Jun 15;21(12):2695-703
pubmed: 25724527
Vasc Cell. 2011 Aug 10;3:18
pubmed: 21831306
Cancer Cell. 2011 Jan 18;19(1):125-37
pubmed: 21251616
Clin Cancer Res. 2013 Mar 15;19(6):1340-6
pubmed: 23271799
Mol Cancer Ther. 2012 Aug;11(8):1650-60
pubmed: 22679110
Cancer Res. 2015 Oct 1;75(19):4086-96
pubmed: 26377940
Oncogene. 2010 Jan 14;29(2):201-13
pubmed: 19838210
Nat Rev Cancer. 2009 Jan;9(1):57-63
pubmed: 19052556
Clin Cancer Res. 2015 Mar 15;21(6):1487-96
pubmed: 25564152
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Dev Cell. 2002 Aug;3(2):167-70
pubmed: 12194848
J Immunother Cancer. 2016 Mar 15;4:12
pubmed: 26981242
Exp Cell Res. 2013 May 15;319(9):1281-8
pubmed: 23328307
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Annu Rev Immunol. 2002;20:197-216
pubmed: 11861602
Sci Transl Med. 2020 Sep 30;12(563):
pubmed: 32998971
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
Cell Adh Migr. 2007 Jul-Sep;1(3):133-6
pubmed: 19262131
Clin Cancer Res. 2008 Jul 15;14(14):4532-42
pubmed: 18628468
Cancers (Basel). 2021 May 13;13(10):
pubmed: 34068065
Cancer Med. 2017 Jan;6(1):245-257
pubmed: 27891816
Clin Chim Acta. 2014 Sep 25;436:243-8
pubmed: 24949865
Cancer Immunol Immunother. 2017 Jan;66(1):1-7
pubmed: 27714433
J Cancer Res Clin Oncol. 2014 Apr;140(4):525-36
pubmed: 24114288
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
Endocrinology. 2008 Jan;149(1):15-9
pubmed: 17916635
Clin Cancer Res. 2012 Oct 1;18(19):5374-86
pubmed: 22952347
BMC Cancer. 2017 Jan 13;17(1):50
pubmed: 28086833
Nat Rev Immunol. 2003 Sep;3(9):745-56
pubmed: 12949498
Clin Exp Metastasis. 2019 Aug;36(4):365-380
pubmed: 31119445
Nat Med. 1995 Feb;1(2):149-53
pubmed: 7585012
Clin Cancer Res. 2017 Oct 1;23(19):5679-5686
pubmed: 28972083
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14
pubmed: 19685283
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7
pubmed: 16751266
Dev Biol. 2012 Dec 15;372(2):157-65
pubmed: 23031691
Oncogene. 2008 Sep 1;27(38):5132-7
pubmed: 18758482
J Natl Cancer Inst. 1982 Sep;69(3):699-708
pubmed: 6180212
Br J Radiol. 1993 Mar;66(783):181-96
pubmed: 7682469
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Oncol Rep. 2018 Jul;40(1):495-503
pubmed: 29749499
Arch Pharm Res. 2012 Aug;35(8):1297-316
pubmed: 22941474
Lancet Oncol. 2019 May;20(5):711-718
pubmed: 30922731
Anticancer Res. 2012 Jun;32(6):2283-93
pubmed: 22641664
Front Mol Biosci. 2022 Jan 21;9:832238
pubmed: 35127830
Microvasc Res. 2015 Sep;101:38-47
pubmed: 26092680
Genes Dev. 2000 Jun 1;14(11):1313-8
pubmed: 10837024
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
Cell. 2009 Jun 12;137(6):1124-35
pubmed: 19524514
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Int Immunol. 2005 Jan;17(1):1-14
pubmed: 15585605
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Br J Cancer. 2020 Sep;123(6):885-897
pubmed: 32713938
Clin Cancer Res. 2020 Oct 1;26(19):5062-5067
pubmed: 32295834
Cancer Res. 1974 Aug;34(8):2109-13
pubmed: 4842257
Gynecol Oncol. 2020 Dec;159(3):721-731
pubmed: 32988624
Ann Surg Oncol. 2016 Dec;23(13):4169-4177
pubmed: 27342831
Nat Med. 2007 May;13(5):552-9
pubmed: 17479101
Br J Cancer. 2010 Jan 5;102(1):134-43
pubmed: 19920829
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Gynecol Oncol Rep. 2020 Jan 02;31:100532
pubmed: 31934607
Reprod Sci. 2013 Apr;20(4):449-55
pubmed: 22995987
Prostate. 2016 Jan;76(1):80-96
pubmed: 26419726
Clin Cancer Res. 2013 Oct 1;19(19):5381-9
pubmed: 23788581
Cancer Res. 2018 Dec 1;78(23):6643-6654
pubmed: 30297531
Clin Cancer Res. 2021 Jan 1;27(1):43-51
pubmed: 33109737
Mol Cancer Ther. 2015 Nov;14(11):2519-26
pubmed: 26333383
Gynecol Oncol. 2019 Apr;153(1):158-164
pubmed: 30630630
Cancer Immunol Res. 2014 Jan;2(1):80-90
pubmed: 24778163
Cell Mol Life Sci. 2008 Oct;65(19):2964-78
pubmed: 18535784
Science. 1994 Sep 9;265(5178):1582-4
pubmed: 7521539
Mol Cancer Ther. 2017 Nov;16(11):2609-2617
pubmed: 28751540